Kura Oncology (NASDAQ:KURA) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research note published on Thursday morning, Benzinga reports. HC Wainwright currently has a $32.00 price objective on the stock.

Other equities research analysts have also issued reports about the stock. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. Wedbush restated an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a research note on Friday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a report on Monday, September 9th. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and dropped their price objective for the company from $26.00 to $19.00 in a report on Monday, October 14th. Finally, UBS Group started coverage on Kura Oncology in a research report on Thursday. They set a “buy” rating and a $27.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $28.83.

Kura Oncology Price Performance

Shares of NASDAQ KURA opened at $17.51 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94. The company has a market cap of $1.34 billion, a price-to-earnings ratio of -7.85 and a beta of 0.84. The stock’s 50-day moving average is $19.34 and its two-hundred day moving average is $20.09. Kura Oncology has a 1-year low of $7.52 and a 1-year high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. The firm’s revenue was up .0% on a year-over-year basis. During the same period last year, the company earned ($0.53) EPS. Analysts forecast that Kura Oncology will post -2.46 EPS for the current fiscal year.

Institutional Trading of Kura Oncology

Large investors have recently made changes to their positions in the company. nVerses Capital LLC acquired a new position in Kura Oncology during the third quarter worth approximately $25,000. SG Americas Securities LLC acquired a new position in shares of Kura Oncology in the 1st quarter valued at $110,000. Saxon Interests Inc. purchased a new stake in Kura Oncology in the 1st quarter valued at $201,000. Quarry LP acquired a new stake in Kura Oncology during the 2nd quarter worth $196,000. Finally, Entropy Technologies LP purchased a new position in Kura Oncology during the 1st quarter worth $218,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.